膀胱癌分子亚型与组织学变异型的瘤内异质性
该回顾性研究对连续膀胱根治性切除标本中的组织学变异型膀胱癌及伴发的常规尿路上皮癌进行分子亚型分析,采用Lund大学分类方法。结果显示93%肿瘤属于尿路上皮样、基因组不稳定或基底鳞状亚型,多组织学患者中39%存在分子异质性,基底鳞状亚型异质性最高(78%与尿路上皮样或基因组不稳定癌共存)。提示分子分型指导治疗时需警惕采样误差。
要点
- 膀胱癌常存在瘤内分子异质性,基底鳞状亚型尤为突出。
- 多组织学患者中39%在不同组织学间显示分子异质性。
- 基于分子分型的临床检测需考虑采样误差风险。
核心结论
- 膀胱癌常具有分子异质性,尤其基底鳞状亚型,可能影响分子分型指导治疗的准确性。
研究设计与样本
- 回顾性连续膀胱根治性切除系列,分析组织学变异型膀胱癌及伴发的常规尿路上皮癌的分子亚型。
主要发现
- 93%肿瘤分类为尿路上皮样、基因组不稳定或基底鳞状亚型。
- 多组织学患者中39%在不同组织学间存在分子异质性。
- 基底鳞状亚型中78%与尿路上皮样或基因组不稳定癌共存(多组织学病例中)。
- 同一患者中未观察到尿路上皮样与基因组不稳定癌共存。
关键数值与推荐
- 分子亚型采用Lund大学方法,纳入细胞周期改变和分化标志物,分为尿路上皮样、基因组不稳定、基底鳞状、间质样和神经内分泌样亚型。
临床怎么用
- 解读膀胱癌分子检测时需考虑瘤内异质性,警惕采样误差。
局限性
- 回顾性研究,样本来自单一机构连续队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular subtyping may inform on prognosis and treatment response in bladder cancer. However, intratumoral molecular heterogeneity is not well studied in this disease and could complicate efforts to use molecular subtyping to guide patient management. To investigate intratumoral heterogeneity in bladder cancer, we examined molecular subtypes in a consecutive, retrospective cystectomy series of histologic variant bladder cancers and conventional urothelial carcinomas co-occurring with them. Molecular subtypes were assigned as per the approach reported by Lund University, an approach that incorporates cell cycle alterations and markers of differentiation, to give the urothelial-like, genomically unstable, basal-squamous, mesenchymal-like, and neuroendocrine-like subtypes. The majority (93%) of tumors were classified as urothelial like, genomically unstable, or basal squamous. Among patients with more than one tumor histology, 39% demonstrated molecular heterogeneity among the different tumor histologies. This was greatest for the basal-squamous subtype, 78% of which co-occurred with either urothelial-like or genomically unstable carcinoma (among cases with multiple histologies). In contrast, there was no co-occurrence of urothelial-like and genomically unstable carcinoma in the same patient. The findings indicate that bladder cancer is often molecularly heterogeneous, particularly in the basal-squamous subtype. This raises the concern for sampling error in laboratory tests that guide therapy based on molecular subtyping. Patient summary: In this report, we investigated molecular diversity among different areas from the same tumor in patients with bladder cancer. We found that different areas from the same tumor are often molecularly different. We conclude that this biological diversity must be taken into account when interpreting clinical molecular tests performed on bladder cancer samples.
引用
- Warrick JI, Sjödahl G, Kaag M, et al. Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. Eur Urol. 2018. PMID: 30266310. doi:10.1016/j.eururo.2018.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。